Sheikh Aziz, Singh Panesar Sukhmeet, Salvilla Sarah, Dhami Sangeeta
Allergy and Respiratory Research Group, Centre for Population Health Services, University of Edinburgh, Edinburgh, UK.
BMJ Clin Evid. 2009 Nov 18;2009:0509.
Hay fever is found throughout the world. Epidemiological evidence suggests considerable geographical variation in its prevalence. Symptoms are caused by an IgE-mediated type 1 hypersensitivity reaction to airborne allergens such as pollen or fungal spores, and may also cause eye, sinus, respiratory, and systemic problems.
We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for hay fever in adolescents and adults? We searched: Medline, Embase, The Cochrane Library, and other important databases up to April 2008 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
We found 211 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
In this systematic review we present information relating to the effectiveness and safety of the following interventions: intranasal corticosteroids, oral antihistamines, intranasal antihistamines, oral leukotriene receptor antagonists, systemic corticosteroids, intranasal ipratropium bromide, oral decongestants, and combinations of these treatments.
花粉热在全球均有发现。流行病学证据表明其患病率存在显著的地域差异。症状是由对花粉或真菌孢子等空气传播过敏原的IgE介导的1型超敏反应引起的，还可能导致眼部、鼻窦、呼吸道和全身性问题。
我们进行了一项系统评价，旨在回答以下临床问题：青少年和成人花粉热治疗方法的效果如何？我们检索了：截至2008年4月的医学期刊数据库（Medline）、荷兰医学文摘数据库（Embase）、考克兰图书馆及其他重要数据库（《临床证据》综述会定期更新；请查看我们的网站获取本综述的最新版本）。我们纳入了来自相关组织如美国食品药品监督管理局（FDA）和英国药品和医疗保健产品监管局（MHRA）的危害警示。
我们发现了211项符合我们纳入标准的系统评价、随机对照试验或观察性研究。我们对干预措施证据的质量进行了GRADE评估。
在本系统评价中，我们提供了以下干预措施的有效性和安全性相关信息：鼻用糖皮质激素、口服抗组胺药、鼻用抗组胺药、口服白三烯受体拮抗剂、全身性糖皮质激素、鼻用异丙托溴铵、口服减充血剂以及这些治疗方法联合使用的情况。
